CNST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CNST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Constellation Pharmaceuticals does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.
The historical data trend for Constellation Pharmaceuticals's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Constellation Pharmaceuticals Annual Data | |||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | ||||||
Shiller PE Ratio | - | - | - | - | - |
Constellation Pharmaceuticals Quarterly Data | ||||||||||||||||||
Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | |
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Constellation Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Constellation Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Constellation Pharmaceuticals's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Constellation Pharmaceuticals does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.
Constellation Pharmaceuticals (NAS:CNST) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Constellation Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Emma Reeve | officer: Chief Financial Officer | C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451 |
Column Group L P | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Karen Valentine | officer: See Remarks | C/O ANTIGENICS INC., 3 FORBES RD, LEXINGTON MA 02421 |
Mark A Goldsmith | director, 10 percent owner | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Jeffrey Humphrey | officer: Chief Medical Officer | C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142 |
Steven L. Hoerter | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Elizabeth Trehu | director | C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138 |
Scott Braunstein | director | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
James E Audia | director | 215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142 |
Adrian Senderowicz | officer: Chief Medical Officer | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Jigar Raythatha | director, officer: See Remarks | C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Patrick Trojer | officer: Chief Scientific Officer | 215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142 |
Richard S Levy | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Ponoi Management, Llc | 10 percent owner, other: General Partner | 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
David V Goeddel | 10 percent owner, other: Managing Partner | C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
From GuruFocus
By Marketwired Marketwired • 02-18-2021
By Marketwired Marketwired • 01-06-2021
By PRNewswire PRNewswire • 06-12-2021
By Marketwired Marketwired • 06-17-2021
By Marketwired Marketwired • 06-02-2021
By PRNewswire PRNewswire • 06-22-2021
By Marketwired Marketwired • 05-10-2021
By Marketwired Marketwired • 04-27-2021
By Marketwired Marketwired • 06-04-2021
By Marketwired Marketwired • 02-24-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.